Deferasirox

Active ingredient: Deferasirox

In short: Deferasirox tablets for oral suspension are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. Deferasirox tablets for oral suspension are indicated for the treatment of chronic iron overload in patients

Forms & strengths•125 mg tabletsOff-white to light yellow, round, flat faced beveled edge, uncoated tablets debossed with “G” and “494” on one side and plain on the other side. …
LabelGlenmark Pharmaceuticals Inc., USA
Label updatedOct 12, 2026

What is Deferasirox used for?

Deferasirox tablets for oral suspension are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Deferasirox tablets for oral suspension are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non- transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L.

The safety and efficacy of deferasirox when administered with other iron chelation therapy have not been established.

âš  Boxed warning (FDA's strongest warning)

Renal Failure

•

Deferasirox can cause acute renal failure and death, particularly in patients with comorbidities and those who are in the advanced stages of their hematologic disorders.

•

Evaluate baseline renal function prior to starting or increasing deferasirox dosing in all patients. Deferasirox is contraindicated in adult and pediatric patients with eGFR less than 40 mL/min/1.73 m2. Measure serum creatinine in duplicate prior to initiation of therapy. Monitor renal function at least monthly. For patients with baseline renal impairment or increased risk of acute renal failure, monitor renal function weekly for the first month, then at least monthly. Reduce the starting dose in patients with preexisting renal disease. During therapy, increase the frequency of monitoring and modify the dose for patients with an increased risk of renal impairment, including use of concomitant nephrotoxic drugs, and pediatric patients with volume depletion or overchelation [see Dosage and Administration (2.1, 2.4, 2.5), Warnings and Precautions (5.1), Adverse Reactions (6.1, 6.2)].

Hepatic Failure

•

Deferasirox can cause hepatic injury including hepatic failure and death.

•

Measure serum transaminases and bilirubin in all patients prior to initiating treatment, every 2 weeks during the first month, and at least monthly thereafter.

•

Avoid use of deferasirox in patients with severe (Child-Pugh C) hepatic impairment and reduce the dose in patients with moderate (Child-Pugh B) hepatic impairment . …

Deferasirox dosage

Deferasirox therapy should only be considered when a patient has evidence of chronic transfusional iron overload. The evidence should include the transfusion of at least 100 mL/kg of packed red blood cells (e.g., at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg), and a serum ferritin consistently greater than 1,000 mcg/L.

Prior to starting therapy or increasing dose, evaluate:

•Serum ferritin level

•Baseline renal function:

•Obtain serum creatinine in duplicate (due to variations in measurements) to establish accurate baseline

•Calculate the estimated glomerular filtration rate (eGFR). Use a prediction equation appropriate for adult patients (e.g., CKD-EPI, MDRD method) and in pediatric patients (e.g., Schwartz equations).

•Obtain urinalyses and serum electrolytes to evaluate renal tubular function [see Dosage and Administration (

Error! Hyperlink reference not valid.

), Warnings and Precautions (

Error! Hyperlink reference not valid.

)].

•Serum transaminases and bilirubin [see Dosage and Administration (

Error! Hyperlink reference not valid.

), Warnings and Precautions (

Error! Hyperlink reference not valid.

)]

•Baseline auditory and ophthalmic examinations

Initiating Therapy

:

The recommended initial dose of deferasirox for patients 2 years of age and older with eGFR greater than 60 mL/min/1.73 m2 is 20 mg per kg body weight orally, once daily. Calculate doses (mg per kg per day) to the nearest whole tablet.

During Therapy

:

•Monitor serum ferritin monthly and adjust the dose of deferasirox, if necessary, every 3 to 6 months based on serum ferritin trends.

•Use the minimum effective dose to achieve a trend of decreasing ferritin.

•Make dose adjustments in steps of 5 or 10 mg per kg and tailor adjustments to the individual patient’s response and therapeutic goals.

•In patients not adequately controlled with doses of 30 mg per kg (e.g., serum ferritin levels persistently above 2,500 mcg/L and not showing a decreasing trend over time), doses of up to 40 mg per kg may be considered. Doses above 40 mg per kg are not recommended .

•Adjust dose based on serum ferritin levels

•If the serum ferritin falls below 1,000 mcg/L at 2 consecutive visits, consider dose reduction, especially if the dose is greater than 25 mg/kg/day .

•If the serum ferritin falls below 500 mcg/L, interrupt deferasirox to minimize the risk of overchelation, and continue monthly monitoring .

•Evaluate the need for ongoing chelation therapy for patients whose conditions no longer require regular blood transfusions.

•Use the minimum effective dose to maintain iron burden in the target range .

•Monitor blood counts, liver function, renal function and ferritin monthly [see Warnings and Precautions (

Error! …

How to take Deferasirox — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Dosing Instructions

Advise patients to take deferasirox tablets once daily on an empty stomach at least 30 minutes prior to food, preferably at the same time every day. Instruct patients to completely disperse the tablets in water, orange juice, or apple juice, and drink the resulting suspension immediately. After the suspension has been swallowed, resuspend any residue in a small volume of the liquid and swallow .

Advise patients not to chew tablets or swallow them whole .

Blood Testing

Advise patients that blood tests will be performed frequently to check for damage to kidneys, liver, or blood cells .

Acute Kidney Injury, Including Acute Renal Failure

Caution patients about the potential for kidney toxicity when taking deferasirox tablets. Inform patients of the signs and symptoms of kidney injury. Advise patients to contact their healthcare provider immediately if they experience any of these symptoms .

Hepatic Toxicity and Failure

Caution patients about the potential for hepatic toxicity when taking deferasirox tablets. Inform patients of the signs and symptoms of hepatic toxicity. …

Warnings & precautions

Do not take this medicine if: Deferasirox tablets for oral suspension are contraindicated in patients with:

•Estimated GFR less than 40 mL/min/1.73 m2

[see Dosage and Administration (

Error! Hyperlink reference not valid.

), Warnings and Precautions (

Error! Hyperlink reference not valid.

)];

•Poor performance status [see Warnings and Precautions (

Error! Hyperlink reference not valid.

,

Error! Hyperlink reference not valid.

)];

•High-risk myelodysplastic syndromes (this patient population was not studied and is not expected to benefit from chelation therapy);

•Advanced malignancies [see Warnings and Precautions (

Error! Hyperlink reference not valid.

,

Error! Hyperlink reference not valid.

)];

•Platelet counts less than 50 x 109/L [see Warnings and Precautions (

Error! Hyperlink reference not valid.

,

Error! Hyperlink reference not valid.

)];

Known hypersensitivity to deferasirox or any component of deferasirox tablets for oral suspension [see Warnings and Precautions (

Error! Hyperlink reference not valid.

), Adverse Reactions (

Error! Hyperlink reference not valid.

)].

Deferasirox is contraindicated in patients with eGFR less than 40 mL/min/1.73 m2. Exercise caution in pediatric patients with eGFR between 40 and 60 mL/minute/1.73 m2. If treatment is needed, use the minimum effective dose and monitor renal function frequently. Individualize dose titration based on improvement in renal injury . For patients with renal impairment (eGFR 40 to 60 mL/min/1.73 m2), reduce the starting dose by 50% [see Dosage and Administration (

Error! Hyperlink reference not valid.

,

Error! Hyperlink reference not valid.

), Use in Specific Populations (

Error! Hyperlink reference not valid.

)].

Deferasirox can cause acute kidney injury including renal failure requiring dialysis that has resulted in fatal outcomes. …

Deferasirox side effects

The following clinically significant adverse reactions are also discussed in other sections of the labeling:

•Acute Kidney Injury, Including Acute Renal Failure Requiring Dialysis, and Renal Tubular Toxicity Including Fanconi Syndrome

•Hepatic Toxicity and Failure

•GI Hemorrhage

•Bone Marrow Suppression

•Hypersensitivity

•Severe Skin Reactions

•Skin Rash

•Auditory and Ocular Abnormalities

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Transfusional Iron Overload

A total of 700 adult and pediatric patients were treated with deferasirox for 48 weeks in premarketing studies. These included 469 patients with beta-thalassemia, 99 with rare anemias, and 132 with sickle cell disease. Of these patients, 45% were male, 70% were Caucasian, and 292 patients were less than 16 years of age. In the sickle cell disease population, 89% of patients were black. Median treatment duration among the sickle cell patients was 51 weeks. Of the 700 patients treated, 469 (403 beta-thalassemia and 66 rare anemias) were entered into extensions of the original clinical protocols. In ongoing extension studies, median durations of treatment were 88 to 205 weeks.

Six hundred twenty-seven (627) patients with myelodysplastic syndrome (MDS) were enrolled across 5 uncontrolled trials. …

Drug interactions

The concomitant administration of deferasirox and aluminum-containing antacid preparations has not been formally studied. Although deferasirox has a lower affinity for aluminum than for iron, do not take deferasirox with aluminum-containing antacid preparations due to the mechanism of action of deferasirox.

Deferasirox may induce CYP3A4 resulting in a decrease in CYP3A4 substrate concentration when these drugs are coadministered. Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive agents, indinavir, fluticasone, lopinavir, lovastatin, lurasidone, maraviroc, midazolam, nisoldipine, pimozide, quetiapine, quinidine, saquinavir, sildenafil, simvastatin, sirolimus, tacrolimus, tolvaptan, tipranavir, triazolam, ticagrelor, and vardenafil) .

Deferasirox inhibits CYP2C8 resulting in an increase in CYP2C8 substrate (e.g., repaglinide and paclitaxel) concentration when these drugs are coadministered. …

About this medicine

Deferasirox is an iron chelating agent. Deferasirox Tablets for Oral Suspension contain 125 mg, 250 mg, or 500 mg deferasirox. Deferasirox is designated chemically as 4-[3,5-Bis (2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]-benzoic acid and its structural formula is:

Deferasirox is a white to slightly yellow powder. Its molecular formula is C21H15N3O4 and its molecular weight is 373.36 g/mol.

Inactive Ingredients: Colloidal silicon dioxide, crospovidone, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone (K-30), sodium lauryl sulfate, and sodium stearyl fumarate.

How it works: Deferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox.

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 59f1d3fb-5bdb-4261-8557-9a4bde8b3c1c. Read the full official label on DailyMed.